Showing 6071-6080 of 9397 results for "".
- La Roche-Posay Debuts New Prebiotic Skincare Linehttps://practicaldermatology.com/news/la-roche-posay-debuts-new-prebiotic-skincare-line/2458323/La Roche-Posay is rolling out a new prebiotic Skincare Line. TOLERIANE Double Repair Moisturizer comes in a full line of products, including an SPF version and two complementary cleansers. The skin's microbiome is comprised of more than 100 b
- La Roche-Posay and George Washington University Publish International Study on Sun Protection Behavior and Skin Cancer Awarenesshttps://practicaldermatology.com/news/la-roche-posay-and-george-washington-university-publish-international-study-on-sun-protection-behavior-and-skin-cancer-awareness/2458327/A large international survey on sun exposure behaviors and skin cancer detection found there are many imperfections and geographical inequalities in primary and secondary prevention of skin cancer. This information could help inform future awareness campaigns developed to address the global need
- Menlo Begins Enrollment for Phase 2 Studies of NK-1 for Pruritushttps://practicaldermatology.com/news/menlo-begins-enrollment-for-phase-2-studies-of-nk-1-for-pruritus/2458325/Menlo Therapeutics Inc. has initiated enrollment in two new Phase 2 trials evaluating a novel neurokinin 1 (NK-1) receptor antagonist, serlopitant, for the treatment of pruritus associated with atopic dermatitis and for the treatment of pruritus fol
- Revance Starts Phase III Program for Injectable Toxin in Frown Lineshttps://practicaldermatology.com/news/revance-starts-phase-iii-program-for-injectable-toxin-in-frown-lines/2458330/Revance Therapeutics began two double-blind, placebo-controlled, North American Phase III trials to evaluate single injections of DaxibotulinumtoxinA (RT002) for the treatment glabellar lines in about 600 total patients. These pivotal trials follo
- Enrollment Complete in BioPharmX's Phase 2b Study of Topical Minocycline Gel for Acnehttps://practicaldermatology.com/news/enrollment-complete-in-biopharmx-phase-2b-study-of-topical-minocycline-gel/2458331/BioPharmX Corporation completed enrollment in the OPAL (tOPicAL Minocycline Gel) study, a Phase 2b dose finding clinical trial to assess the efficacy and safety of BPX-01 for the treatment of acne vulgaris. The 12-week, multi-center, randomized, dou
- Provectus Biopharmaceuticals Terminates CEO and COOhttps://practicaldermatology.com/news/provectus-biopharmaceuticals-terminates-ceo-and-coo/2458335/Provectus Biopharmaceuticals, Inc.'s Board of Directors unanimously voted to terminate Peter R. Culpepper, effective immediately, from all positions held with the company, including Chief Executive Officer and Chief Operating Officer, for cause in accordance with the terms of his employment a
- Skin Cancer Foundation: Bill Ridenour Is New Senior Director of Partnership Developmenthttps://practicaldermatology.com/news/skin-cancer-foundation/2458333/The Skin Cancer Foundation has appointmented Bill Ridenour to the role of senior director of partnership development. Ridenour’s career has spanned over 30 years in the advertising industry and this new position marks a switch to the nonprofit sector. Prior to his appointment, Ridenour
- La Roche-Posay Nabs 20 Beauty Awards in 2016https://practicaldermatology.com/news/la-roche-posay-nabs-20-beauty-awards-in-2016/2458336/La Roche-Posay (LRP) won 20 beauty awards, almost doubling its wins from the previous year, the company has announced. The awards, judged by editors, industry leaders and elite experts who test thousands of beauty products before awarding top honors, bring the total skincare wins for LRP to 55 an
- EZDERM Partners With Healthmonix to Provide Integrated MIPS Reporting for Dermatologistshttps://practicaldermatology.com/news/ezderm-partners-with-healthmonix-to-provide-integrated-mips-reporting-for-dermatologists/2458337/EZDERM, LLC and Healthmonix have partnered to integrate the MIPSPRO platform into the EZDERM suite of dermatology software solutions, including the integrated EZDERM Electronic Health Record and Practice Management systems. This partnership gives EZDERM clients access to education,
- Dermavant Licenses Portola Pharma's Cerdulatinib For Skin Applicationshttps://practicaldermatology.com/news/dermavant-licenses-portola-pharmas-cerdulatinib-for-skin-applications/2458338/Dermavant Sciences has licensed cerdulatinib from Portola Pharma for topical dermatologic applications. Cerdulatinib is a dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor that Portola is developing to treat patients